<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In the United States, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is the second most frequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> and the fourth most common cause of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="2981">Baicalin</z:chebi>, <z:chebi fb="0" ids="24043">a flavone</z:chebi> derivative isolated and purified from the dry root of Scutellaria, was assessed for its antitumor effects in human SW620 <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2981">Baicalin</z:chebi> (200 μM) inhibited proliferation of SW620 cells </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="2981">Baicalin</z:chebi> (200 μM) increased activities of caspase-3, -8, and -9 in SW620 cells </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, flow cytometric analysis of <z:chebi fb="0" ids="2981">baicalin</z:chebi>-treated SW620 cells showed an increase in sub-G1 cells, and the dihydroethidium assay showed significant enhancement of intracellular <z:chebi fb="39" ids="44785">peroxide</z:chebi> production in <z:chebi fb="0" ids="2981">baicalin</z:chebi>-treated cells </plain></SENT>
<SENT sid="5" pm="."><plain>Addition of <z:chebi fb="0" ids="28939">N-acetylcysteine</z:chebi> prevented most of the <z:chebi fb="0" ids="2981">baicalin</z:chebi>-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, which in turn mediated cytotoxicity in human SW620 cells </plain></SENT>
<SENT sid="6" pm="."><plain>In vivo, <z:chebi fb="0" ids="2981">baicalin</z:chebi> (50 mg/kg/day, i.p.) treatment inhibited 55% of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in xenografted <z:mp ids='MP_0003815'>nude</z:mp> mice by 4 weeks, compared to that of the vehicle control (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="2981">Baicalin</z:chebi> had no noteworthy influence on body weight </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, we suggest the development of <z:chebi fb="0" ids="2981">baicalin</z:chebi> as a potential leading antitumor agent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>